Lymphoplasmacytic lymphoma surgery: Difference between revisions
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Lymphoplasmacytic lymphoma}} | {{Lymphoplasmacytic lymphoma}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{S.M.}} | ||
==Overview== | ==Overview== | ||
Surgery is not the first-line treatment option for patients with Waldenström macroglobulinemia. [[Stem cell transplant]] is usually reserved for patients with either relapse or refractory Waldenström macroglobulinemia. | |||
Surgery is not the first-line treatment option for patients with | |||
==Surgery== | ==Surgery== | ||
Revision as of 21:16, 13 February 2019
|
Lymphoplasmacytic lymphoma Microchapters |
|
Differentiating Lymphoplasmacytic Lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Lymphoplasmacytic lymphoma surgery On the Web |
|
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma surgery |
|
Risk calculators and risk factors for Lymphoplasmacytic lymphoma surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
Overview
Surgery is not the first-line treatment option for patients with Waldenström macroglobulinemia. Stem cell transplant is usually reserved for patients with either relapse or refractory Waldenström macroglobulinemia.
Surgery
Stem cell transplant is usually reserved for patients with either relapse or refractory Waldenström's macroglobulinemia.[1]
References
- ↑ Waldenström's macroglobulinemia: prognosis and management. Blood Cancer Journal (2015) http://www.nature.com/bcj/journal/v5/n3/full/bcj201528a.html Accessed on November 13, 2015